{"id":130833,"date":"2026-10-27T13:11:54","date_gmt":"2026-10-27T07:41:54","guid":{"rendered":"https:\/\/vajiramandravi.com\/current-affairs\/?p=130833"},"modified":"2026-10-27T13:55:46","modified_gmt":"2026-10-27T08:25:46","slug":"sglt2-inhibitors","status":"publish","type":"post","link":"https:\/\/vajiramandravi.com\/current-affairs\/sglt2-inhibitors\/","title":{"rendered":"Study Examines SGLT2 Inhibitor Benefits and Risks in Adults Aged 80 and Above"},"content":{"rendered":"<h2><b>SGLT2 Inhibitors Latest News<\/b><\/h2>\n<p style=\"text-align: justify;\"><span style=\"font-weight: 400;\">New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD).<\/span><\/p>\n<h2><b>About SGLT2 Inhibitors<\/b><\/h2>\n<ul>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">SGLT2 (<\/span><b>Sodium-Glucose Cotransporter-2<\/b><span style=\"font-weight: 400;\">) inhibitors are a class of <\/span><b>medications <\/b><span style=\"font-weight: 400;\">primarily used to <\/span><b>treat <a href=\"https:\/\/vajiramandravi.com\/current-affairs\/type-2-diabetes-t2d\/\" target=\"_blank\">Type 2 diabetes (T2D)<\/a>.\u00a0<\/b><\/li>\n<li style=\"text-align: justify;\"><b>T2D<\/b><span style=\"font-weight: 400;\">, the <\/span><b>most common type of diabetes,<\/b><span style=\"font-weight: 400;\"> is a disease that occurs when your <\/span><b>blood glucose<\/b><span style=\"font-weight: 400;\">, also called blood sugar, is <\/span><b>too high.\u00a0<\/b><\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">SGLT2 Inhibitors<\/span><b> manage your blood sugar<\/b><span style=\"font-weight: 400;\"> by <\/span><b>helping your kidneys remove extra glucose through your pee.\u00a0<\/b><\/li>\n<li style=\"text-align: justify;\"><b>How do SGLT2 inhibitors work?<\/b>\n<ul>\n<li style=\"text-align: justify;\"><b>SGLT2 <\/b><span style=\"font-weight: 400;\">is a<\/span><b> protein in your kidney<\/b><span style=\"font-weight: 400;\">s that <\/span><b>reabsorbs glucose.\u00a0<\/b><\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Typically, when glucose in your blood flows through your kidneys, some glucose goes back into your bloodstream.\u00a0<\/span><\/li>\n<li style=\"text-align: justify;\"><b>SGLT2 inhibitors block that process<\/b><span style=\"font-weight: 400;\">, so your <\/span><b>kidneys don\u2019t reabsorb glucose.\u00a0<\/b><\/li>\n<li style=\"text-align: justify;\"><b>Instead, it comes out in your pee.<\/b><span style=\"font-weight: 400;\"> This means the glucose doesn\u2019t get into your bloodstream and raises your blood sugar.\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">The use of SGLT2 inhibitors goes beyond managing blood sugar.\u00a0<\/span>\n<ul>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">They also <\/span><b>help improve kidney and heart health<\/b><span style=\"font-weight: 400;\"> for people with chronic kidney disease (CKD) or heart failure.\u00a0<\/span><\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">They can <\/span><b>slow the progression of kidney disease<\/b><span style=\"font-weight: 400;\"> and reduce the risk of needing dialysis.\u00a0<\/span><\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">SGLT2 inhibitors also <\/span><b>lower the risk of heart failure flare-ups.\u00a0<\/b><\/li>\n<\/ul>\n<\/li>\n<li style=\"text-align: justify;\"><b>Common SGLT2 inhibitors<\/b>\n<ul>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Dapagliflozin<\/span><\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Empagliflozin<\/span><\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Canagliflozin<\/span><\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Ertugliflozin<\/span><\/li>\n<\/ul>\n<\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Some of the <\/span><b>side effects<\/b><span style=\"font-weight: 400;\"> include:<\/span>\n<ul>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Higher risk of developing<\/span><b> genital and urinary tract infections<\/b><\/li>\n<li style=\"text-align: justify;\"><b>Urinating more frequently<\/b><\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Flu like symptoms<\/span><\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Nausea<\/span><\/li>\n<li style=\"text-align: justify;\"><span style=\"font-weight: 400;\">Joint pain<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><b>News: <\/b><a href=\"https:\/\/www.news-medical.net\/news\/20261026\/Geriatric-chronic-kidney-disease-patients-benefit-from-SGLT2-inhibition.aspx\" target=\"_blank\" rel=\"nofollow noopener\"><b>NM<\/b><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>New research examines how SGLT2 inhibitors may benefit or pose risks for adults aged 80 and above living with chronic kidney disease, highlighting the need to assess evidence in older patients.<\/p>\n","protected":false},"author":23,"featured_media":130791,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[11181],"class_list":["post-130833","post","type-post","status-publish","format-standard","has-post-thumbnail","category-upsc-prelims-current-affairs","tag-sglt2-inhibitors","no-featured-image-padding"],"acf":[],"_links":{"self":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/130833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/comments?post=130833"}],"version-history":[{"count":5,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/130833\/revisions"}],"predecessor-version":[{"id":130869,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/130833\/revisions\/130869"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media\/130791"}],"wp:attachment":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media?parent=130833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/categories?post=130833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/tags?post=130833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}